Alector, Inc(NASDAQ:ALEC) 
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Park...
Website: http://alector.com
Founded: 2013
Full Time Employees: 162
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 1.06
H 1.08
L 1.01
C 1.02
V 820,940
10EMA 1.02
20EMA 1.02
60EMA 1.02
120EMA 1.02
250EMA 1.02